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Abstract
Discovery of novel biomarkers for atherosclerosis is important to aid in early diagnosis of pre-symptomatic patients at high risk of cardiovascu-
lar events. The aim of the present study was therefore to identify potential biomarkers in circulating cells reflecting atherosclerotic lesion pro-
gression in the vessel wall. We performed gene arrays on circulating leucocytes from atherosclerosis prone Apoe/ mice with increasing ages,
using C57BL/6 mice as healthy controls. We identified fatty acid binding protein 4 (FABP4) mRNA to be augmented in mice with established dis-
ease compared with young Apoe/ or controls. Interestingly, the transcript FABP4 correlated significantly with lesion size, further supporting a
disease associated increase. In addition, validation of our finding on protein level showed augmented FABP4 in circulating leucocytes whereas,
importantly, no change could be observed in plasma. Immunofluorescence analysis demonstrated FABP4 to be present mainly in circulating
neutrophils and to some extent in monocytes. Moreover, FABP4-positive neutrophils and macrophages could be identified in the subintimal
space in the plaque. Using human circulating leucocytes, we confirmed the presence of FABP4 protein in neutrophils and monocytes. In conclu-
sion, we have showed that cellular levels of FABP4 in circulating leucocytes associate with lesion development in the experimental Apoe/
model. The increased expression is primarily localized to neutrophils, but also in monocytes. We have identified FABP4 in leucocytes as a poten-
tial and easy accessible biomarker of atherosclerosis which could be of future clinical relevance.
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Introduction
Atherosclerosis is a systemic disease of the arterial system character-
ized by lipid accumulation and inflammation in the vessel wall [1–3].
The disease is silent during decades until a usually sudden acute clini-
cal manifestation occurs, such as a myocardial infarction or stroke.
Although risk scoring models such as the Framingham model offers
some individual prediction, many adverse cardiovascular events do
occur in undiagnosed and asymptomatic individuals. Several inflam-
matory mediators in the circulation associate with increased cardio-
vascular risk and have been proposed as biomarkers, even though
they only rarely add to the Framingham risk score (FRS). The utility of
CRP is under debate [4, 5] and several other risk markers, including
adiponectin, MMP-9 and IL-18, are being investigated [6]. It is impor-
tant to note that FRS classifies risk over a period of 10 years, rather
than in the near future within 1 year. A model that accurately calcu-
lates near-term risk of adverse cardiovascular events in diverse popu-
lations is still lacking [7]. This has prompted a search for novel
biomarkers of atherosclerotic disease to improve identification of high
risk patients by adding information about short-term risk to current
risk prediction models.
We suggested that circulating inflammatory cells may carry sig-
nals with biomarker potential that may reveal progression of athero-
sclerotic disease, which is an important underlying risk factor for
developing adverse cardiovascular events in the near future. We
therefore investigated potential biomarkers reflecting disease devel-
opment in circulating leucocytes using the atherosclerosis prone
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Apoe/ mouse model. To cover different stages of plaque develop-
ment, from onset of disease with fatty streak formation to presence
of late stage atherosclerotic lesions, the atherosclerotic mice were
investigated at three different time-points. From an unbiased strategy,
we identified cellular FABP4 expression in circulating leucocytes to be
associated with the extent of atherosclerosis.
Materials and methods
Animals
All animal experiments were approved by the regional ethics committee
for animal research in Stockholm [N82/09] and conform to the Directive
2010/63/EU of the European Parliament. Four sets of female Apoe/
and C57BL/6 mice were used. All mice were fed standard chow (R70,
Lantm€annen, Stockholm, Sweden).
Lesion analysis
Three groups of Apoe/ mice, killed at 12, 20 and 32 weeks, and one
group of C57BL/6 control animals killed at 85 weeks of age were stud-
ied. All animals were killed under CO2, blood was collected by cardiac
puncture and sampled in EDTA tubes. The vasculature was perfused
with sterile PBS before the descending thoracic aorta was dissected.
The aortas were fixed in 4% formaldehyde, opened longitudinally, pin-
ned onto wax plates, and stained with Sudan IV (Merck AG, Darmstadt,
Germany). Aortic lesion areas were calculated with Leica Q500MC soft-
ware.
Plasma analysis
Alanine aminotransferase (ALT), creatine kinase myocardial band
(CKMB) and creatinine (CRSC) were determined by Vitros DT60II
(Ortho-Clinical Diagnostics, Raritan, NJ, USA).
RNA, microarrays and RT-PCR
RNA from blood leucocytes was isolated using RNeasy-kit according to
the manufacturer’s protocol (QIAGEN Inc., Hilden, Germany) with a
DNase step. RNA quantity and quality were assessed using a Bioanalyz-
er (Agilent Technologies, Palo Alto, CA, USA). Equal amount of RNA
from individual mice was pooled (n = 6–8 per group) in each age
group. Each group was analysed by Affymetrix microarray, MOE430A.
In addition, specific transcripts were analysed by TaqMan RT-PCR with
ABI Prism7700 sequence detector and software (Applied Biosystems,
Foster City, CA, USA) in the individual RNA samples to validate array
findings. An additional group was added to investigate FABP4 mRNA in
Apoe/ and C57Bl6 aged 8 weeks. The primer/probe set used were;
FABP4: Mm00445878_m; CD36: Mm00445878_m1 and as house-keep-
ing gene, HPRT: Mm00446968_m1. Data were analysed on the basis of
the relative expression with the formula 2ΔΔCT, where ΔΔCT = ΔCT
(sample)ΔCT (calibrator=average CT values of all sample values within
each group), and ΔCT is the CT value of the house-keeping gene sub-
tracted from the CT value from the sample.
Differential leucocyte count and ELISA assay of
FABP4
Blood was drawn in EDTA tubes from an additional set of Apoe/ mice
aged 10–11 weeks, 20–22 weeks and 35–37 weeks (n = 7–8/group).
To analyse total numbers of WBC and platelets, differential counts of
lymphocytes, monocytes, granulocytes and platelets were run on an
Animal Blood Counter machine (ScandiVet, Enk€oping, Sweden). Plasma
was collected after 1500 9 g centrifugation for 10 min., RBC lysed with
EL-buffer (Qiagen, Sollentuna, Sweden) and protein from the leucocytes
isolated with T-Per Tissue Protein Extraction Reagent with recom-
mended protease inhibitors (Thermo Scientific, Rockford, IL USA).
Plasma levels and cellular levels of FABP4 protein were determined by
mouse FABP4 ELISA, MBS366055 (MyBioSource, San Diego, CA, USA).
Flow cytometry
Apoe/ and C57BL/6 mice, 12, 20 and 32 weeks of age (n = 8 per
group) were killed and blood collected for FACS analysis. After lysis of
red blood cells, Fc-receptor blockage was performed with anti-CD16/
CD32 (BD Pharmingen, San Diego, CA, USA), before staining with pri-
mary conjugated antibodies to investigate the monocyte populations
(see list below). Data were acquired, immediately after staining, using a
CyAn ADP cytometer (Beckman Coulter, High Wycombe, UK) and analy-
sed with the software Summit (DAKO, CO, USA). The following antibod-
ies were used; antimouse CD45R/B220-PE (Biolegend, Uithoorn, The
Netherlands), Ly6G-Pacific Blue, CD11b PE-Cy7, CD11c-APC, Ly6C-
FITC, CD49b(DX5)-PE, NK1.1-PE, CD3-PE (BD, San Jose, CA, USA).
Immunofluorescence staining
Leucocytes were isolated and centrifuged at 400 r.p.m., 5 min., onto
Super-Frost glass slides (100,000 cells/spot) before fixation in ice-cold
paraformaldehyde (PFA) for 10 min. Cells were blocked with avidin/bio-
tin and 5% serum, following incubation with primary antibody against
FABP4 in 0.1% tween at 4°C over night. The following day, secondary
antibody anti-rabbit DyLight488 (1:200) was added for 1 hr. For double
staining, a second primary antibody (see list and vendors below) was
added for 1 hr in RT, followed by a biotinylated antibody before strepta-
vidin labelled DyLight594 (1:200). Nuclei were stained with DAPI
(Sigma-Aldrich, Saint-Louis, MO, USA) before mounting and analysis
with a Leica TCS-SP5 confocal microscope.
In addition, 10-lm cryostat sections cut from the aortic root were
analysed for the presence of FABP4 in combination with Ly6G or CD68,
using the same staining protocol as above. For all stainings, appropri-
ate isotype controls were used. Antibodies used: Primary: FABP4 rabbit
antimouse, CD3 hamster antimouse (Abcam, Cambridge, MA, USA),
B220 rat antimouse, Ly6G rat antimouse (Biolegend, Uithoorn, The
Netherlands) and CD68 rat antimouse (AbD Serotec, Oxford, UK).
Secondary: Biotinylated horse anti-rat, biotinylated goat anti-hamster,
streptavidin-DyLight 594 and goat anti-rabbit Alexa488 (Vector Labs,
Peterborough, UK).
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Immunofluorescence staining of human
leucocytes
Blood was drawn from four healthy controls in EDTA tubes as approved
by Stockholm Regional Ethical committee [D.nr. 2005/880-31/3]. Leuco-
cytes were isolated and centrifuged at 400 r.p.m., 5 min., onto Super-
Frost glass slides (100,000 cells/spot) before fixation in PFA for
10 min. Following the protocol above, staining was made with the fol-
lowing antibodies: Primary: FABP4 rabbit anti-human (Abcam), CD66b
mouse anti-human (Fitzgerald, Acton, MA, USA) and CD14 mouse anti-
human (Becton Dickinson, Franklin Lakes, NJ, USA). Secondary: biotiny-
lated horse antimouse, streptavidin-DyLight594, and goat anti-rabbit
Alexa488 (Vector Labs, Peterborough, UK).
Results
Increased levels of FABP4 mRNA in circulating
leucocytes in Apoe/ mice with progression of
atherosclerosis - independent of ageing
Gene expression profiles in leucocytes from atherosclerotic Apoe/
mice were analysed to identify if any atherosclerosis-related changes
could be detected in circulating cells. The atherosclerotic mice were
investigated at three different time-points, 12, 20 and 32 weeks of
age, to cover different stages of plaque development. To adjust for
any changes correlating to ageing rather than atherosclerosis, the
non-atherosclerotic C57BL/6 mouse was used as control. When com-
paring the transcript profiles between Apoe/ and control mice, we
revealed FABP4 to be the most changed transcript in the circulating
leucocytes (Fig. 1A). The transcript level of FABP4 between young
(8 weeks old) Apoe/ and control mice did not differ, as measured
by real-time RT-PCR (Fig. 1B). Neither, ALT, CKMB or CRSC differed
between the mice groups, indicating normal status of liver, heart and
kidney (data not shown).
FABP4 mRNA expression in circulating
leucocytes correlates with lesion size
To validate our array finding, real-time RT-PCR was performed from
isolated leucocyte RNA of the individual Apoe/ mice. For quantita-
tive lesion measurement, dissected thoracic aortas were pinned and
stained with Sudan IV to measure lesion percentage. The lesion per-
centage was as expected with a mean of 0.4% in the 12 weeks age
group, 3% in the 20 week and 11% in the 32 weeks age group
(Fig. 2A). Correlation of lesion size in aorta and mRNA expression of
FABP4 in circulating leucocytes gave an r = 0.800, ***P < 0.0001
(Fig. 2B).
FABP4 and its relation to CD36 on mRNA level
Our time-course study of circulating leucocytes also identified an
increase in CD36 mRNA level, positively correlated with FABP4 mRNA
level (r = 0.594 **P < 0.001) and to lesion size (r = 0.675,
***P < 0.0001; Supporting Information Figure S1A and B). However,
the correlation with disease development was less robust than that
observed with FABP4.
The FABP4 protein is augmented in circulating
leucocytes and unchanged in plasma in Apoe/
mice
We repeated our time-course study, this time for protein analysis and
differential count. Blood was drawn in EDTA tubes from Apoe/ mice
(10–11, 20–22 and 35–37 weeks of age), plasma collected and pro-
tein extracts from leucocytes isolated to analyse leucocyte FABP4
protein content by ELISA. One aliquot of the sample was analysed in
parallel by differential count of leucocytes. ELISA analysis demon-
strated a cellular increase in FABP4, with no corresponding change in
protein levels detected in the plasma comparing the different groups
A B
Fig. 1 FABP4 mRNA levels in circulating leucocytes. (A) Gene arrays on circulating leucocytes show increased mRNA levels of FABP4 in 20 and
32 weeks old Apoe/, as compared to 12 weeks old Apoe/. C57BL/6, 85 weeks of age, were used as controls. One array per age group was run
on pooled RNA (n = 6–8) from circulating leucocytes. (B) mRNA levels of FABP4 in circulating leucocytes from Apoe/ and C57Bl6 (8 weeks of
age) measured by RT-PCR TaqMan (n = 10–11).
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(Fig. 3A and B). The plasma concentrations of FABP4 in C57BL/6
were not altered with ageing, comparing 10, 20 and 32 weeks of age
(data not shown).
Differential leucocyte cell counts in Apoe/ did not reveal any
major changes in total cell numbers, except for an increase in platelet
concentration (Supporting Information Table S1). From these analy-
ses, we concluded that the changes in FABP4 mRNA levels and pro-
tein expression were not due to increases of a specific leucocyte
population.
The inflammatory monocyte subset constitutes
the major part of the monocytic population
preceding advanced stages of atherosclerosis
Flow cytometric analyses were performed on whole blood. Monocytes
were identified as CD3, B220, DX5 NK1.1 C11cmi, CD11b+,
Ly6G and Ly6C+. The monocytes were further analysed as Ly6Chi or
Ly6Clo. In Apoe/ 12 weeks and 20 weeks of age, the inflammatory
Ly6Chi monocyte subtype constituted the greater part of all the
CD11b+Ly6C+ monocytes. This distribution changed in the 32-week-
old animals, where the percentage of Ly6Chi and Ly6Clo was equal
(Supporting Information Figure S2A and C). In C57BL/6 mice, the
percentage between the inflammatory and non-inflammatory mono-
cyte populations did not differ significantly (Figure S2B).
FABP4 is expressed by neutrophils and
monocytes
To determine cell type in the circulation with FABP4 expression, we
performed immunohistochemical analysis. Leucocytes from both
the Apoe/ and C57BL/6 were deposited by cytospin and stained
with FABP4 antibody, combined with cell markers for T cells (CD3),
A B
Fig. 2 Levels of FABP4 mRNA in circulating leucocytes correlates with extent of atherosclerotic lesion in aorta. (A) Percent lesion area of total vessel
area (n = 6–8 per group). (B) mRNA levels of FABP4 in circulating leucocytes from Apoe/ (12, 20 and 32 weeks of age) measured by RT-PCR
TaqMan and correlated with percentage of lesion size (r = 0.800, ***P < 0.0001; n = 22).
A B
Fig. 3 FABP4 protein level increases in circulating leucocytes in Apoe/ with disease progression, but is stable in plasma. (A) Cellular protein level
in circulating leucocytes of FABP4 in Apoe/ (10–11, 20–22 and 35–37 weeks of age) as measured by ELISA (n = 7–8 per group). (B) FABP4 con-
centrations in plasma in Apoe/ (10–11, 20–22 and 35–37 weeks of age) as measured by ELISA (n = 7–8 per group). ***P < 0.0001 versus
Apoe/ 20w, *P < 0.05 versus Apoe/ 32w. ns indicates not significant.
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B cells (B220), monocytes (CD68) and neutrophils (Ly6G). Neither
T, nor B cells, showed any expression of FABP4 in either of the
mice strains at the different ages analysed (12, 20 and 32 weeks
of age; Fig. 4A and B). The neutrophils turned out to be the cell
type in the circulation with strongest FABP4 expression in all ages
analysed and in both strains (Fig. 4C). Monocytes, defined as
CD68+ cells also stained with FABP4, but to a lesser extent
(Fig. 4D).
In murine atherosclerotic lesions, FABP4 was found to be local-
ized mainly to the subintimal space (Fig. 4E and F). Both Ly6G+ neu-
A1 A2
B1 B2
C1 C2
D1 D2
E1 E2
E3 E4
F1 F2
F3 F4
Fig. 4 Immunofluorescent staining of FABP4 and leucocytes in the circulation of Apoe/ mice. (A–D) Immunofluorescent staining of leucocytes
from Apoe/ 32 weeks of age with FABP4 (in green) with the T cell marker CD3 (A), the B cell marker B220 (B), the neutrophil marker Ly6G (C)
and the monocyte/macrophage marker CD68 (D) (all in red). Nuclei stained blue. White bar is 10 lm. (E–F) Immunofluorescent staining of athero-
sclerotic lesions from Apoe/ 32 weeks of age with FABP4 (in green) in combination with the neutrophil marker Ly6G (E) and the monocyte/mac-
rophage marker CD68 (F). Nuclei stained blue. White bar is 10 lm.
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trophils and CD68+ macrophages positive for FABP4 were identified
in the lesion (Fig. 4E and F).
In humans, FABP4 is expressed by neutrophils
and monocytes in the circulation
From blood samples drawn from healthy human beings, peripheral
circulating blood cells were purified and analysed in the same way as
with the murine cells. IHC analysis was performed with the neutrophil
marker CD66b (CEACAM8) and the monocyte marker CD14, to inves-
tigate human expression pattern. Interestingly, both cell populations
turned out to be positive for FABP4 (Fig. 5A and B).
Discussion
The aim of our study was to identify markers in the circulation outside
the plaque itself which correlate to the development of atherosclerotic
disease before onset of symptoms. By using unbiased transcript pro-
filing to map changes over time in circulating leucocytes in Apoe/
mice and non-atherosclerotic control mice, we identified FABP4 in cir-
culating neutrophils and to a weaker extent in monocytes as the major
changed transcript with regard to progression of atherosclerotic dis-
ease. We also demonstrated that increased cellular FABP4 protein is
specifically upregulated in circulating leucocytes and that no spill-
over to plasma occurred as levels of FABP4 in plasma remained
unchanged. These findings suggest that cellular mRNA signatures
may serve as early biomarkers. Moreover, we demonstrated FABP4 in
neutrophils, as well as in macrophages in the murine atherosclerotic
lesion. In addition, neutrophils and monocytes from healthy human
blood donors are also shown to contain FABP4.
Several studies, both in experimental models and human data,
have shown FABP4 to be involved in atherosclerotic lesion
progression [8–11]. FABP4 is a 15 kD cytoplasmic protein binding
hydrophobic ligands, such as unsaturated and saturated fatty acids
and eicosanoids, but the exact biological function(s) are still unknown
[12]. FABP4 was initially identified as a key protein in adipocyte differ-
entiation and has later been shown in macrophages, foam cells [13]
and immune competent dendritic cells [14].
We previously demonstrated augmented FABP4 expression in the
human atherosclerotic lesion to be associated with unstable plaque
phenotype [15], this was later confirmed by others [16, 17]. In addi-
tion, levels of FABP4 in established atherosclerotic plaques correlate
with increased risk for cardiovascular events during follow-up, inde-
pendent from medication, serological or general risk factors [16, 17].
Although it is of major interest to understand complex processes
within the lesion to gain knowledge of the pathogenesis, the lesion
per se is quite impractical for direct access to measure biomarkers.
The fact that atherosclerosis is a chronic systemic inflammatory dis-
ease may imply that circulating blood cells possess the potential to
mirror an ongoing atherosclerotic disease process. It would, in fact,
be advantageous if specific biomarker measurements could be per-
formed on circulating blood cells because they are easy to sample,
and the subsequent mRNA/protein measurements are relatively quick
and cheap. A recent study suggested the future use of a ‘multi-gene
biomarker model’ across different sets of leucocytes when predicting
early stage atherosclerosis in asymptomatic patients [18]. Our pres-
ent study using gene transcript profiling and protein measurements
in circulating blood cells from an experimental model, demonstrate
FABP4 to be a robust marker of the extent of atherosclerosis. Inter-
estingly, the protein level of FABP4 in the plasma of neither control
nor Apoe/ mice change with age or with disease progression, sug-
gesting that cellular upregulation in leucocytes is an early event in
disease progression. The lack of an increase in plasma protein levels
suggests that plasma FABP4 levels may not necessarily derive from
circulating leucocytes or may be a later event downstream of cellular
upregulation. Nevertheless, cellular measurement may be preferred
A B
Fig. 5 Human neutrophils and monocytes are positive for FABP4. Human leucocytes were stained with FABP4 (green) and the monocyte marker
CD14 (A) or the neutrophil marker CD66b (B). Nuclei stained blue with DAPI, as seen in the small imbedded photos in the left hand corner of A and
B. White bar 5 lm.
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for early detection. In addition, we also observed a correlation with
the membrane glycoprotein CD36 mRNA in circulating cells to lesion
size and to FABP4 expression. CD36 is a class B scavenger receptor
known to be expressed on a wide variety of cells, in particular on
monocytes and macrophages, and has a role in uptake of oxidatively
modified low-density lipoprotein (LDL) as well as other ligands. The
possible mechanistic role of the relationship between FABP4 and
CD36 is not clarified from this study, but could speculatively involve
increased cellular lipid uptake and thus increased intracellular lipid
loading but further investigations are needed.
In the circulation, we found FABP4 to be present mainly in neu-
trophils but also in monocytes. Neutrophils communicate avidly with
other immune cells such as monocytes/macrophages, T lymphocytes
and dendritic cells but also endothelial cells and smooth muscle cells,
via direct cell contact and the release of mediators. In addition, neu-
trophils are producers of the potent leucocyte chemoattractant lipid
mediator LTB4 [19] and FABP4 has the capacity to bind inflammatory
lipid precursors, leukotrienes and stabilize LTA4 in vitro [20]. We
have previously shown a correlation in the human atherosclerotic
lesion between FABP4 mRNA and the leukotriene enzymes 5-LO and
LTA4H mRNA [15]. It is therefore tempting to speculate that the
increased expression of FABP4 within these cells, would relate to
increased production of LTB4. In the murine atherosclerotic plaque,
we observed FABP4-positive neutrophils in the shoulder regions and
close to the subintimal space in the murine plaque. Given their short
life span in inflamed tissues, neutrophils have retained little attention
in atherosclerosis up until recently [21, 22]. New evidence suggests
that these cells can contribute and play a major role in orchestrating
the inflammatory response in atherosclerotic disease. By using intra-
vital microscopy it has been shown that a majority of leucocytes inter-
acting with the endothelium on lesion shoulders are neutrophils,
which would imply recruitment of these cells to the plaque [23, 24].
Once in the vessel wall, neutrophils are known to rapidly become
apoptotic [25] and release ‘find-me’ and ‘eat-me’ signals to attract
macrophages for scavenging [26]. In addition to FABP4-positive neu-
trophils in the lesion, we also found FABP4-positive macrophages
throughout the lesion. Compared with the CD68-positive cells in the
circulation, the macrophages within the lesion express more FABP4.
We speculate that, in addition to the known upregulation of FABP4
during foam cell formation, scavenging of apoptotic cells might result
in augmented FABP4 expression in the lesional macrophages/foam
cells.
As mentioned previously, immunohistochemistry of the circulat-
ing leucocytes from control and Apoe/ mice reveal a weak FABP4
staining in some monocytes. The monocytes can be divided into the
more inflammatory Ly6Chigh and the less inflammatory Ly6Clow sub-
population [27]. By flow cytometry, we observed a significant higher
percentage of the Ly6Chigh subset in 12 and 20 weeks old Apoe/
mice. This is in contrast to later stage of disease and during all time-
points investigated for C57/BL6, where the distribution of Ly6Chigh
and Ly6Clow is similar. Both subsets are known to infiltrate the athero-
sclerotic lesions, although Ly6Chigh are more robustly recruited [28].
In the future, it would be of interest to pinpoint the activation status
of the different FABP4-positive monocyte/macrophage and neutrophil
populations in the circulation as well as within the murine lesion.
In human circulating leucocytes, we also detected FABP4 protein
in monocytes and neutrophils. Studies have demonstrated neutroph-
ils at the site of plaque erosion or rupture, in specimens from patients
with unstable angina and in samples from patients having an acute
MI [29, 30]. Furthermore, high neutrophil numbers in carotid athero-
sclerotic plaques have been associated with unstable plaques [29].
These findings make it highly relevant to further investigate the role
of neutrophils containing FABP4 and their possible role as disease bi-
omarker in atherosclerosis.
In conclusion, our main findings in this study show (a) cellular
levels of FABP4 in the circulating leucocytes to associate with
lesion development in Apoe/ and (b) FABP4 to be expressed by
the neutrophils and monocytes in the circulation. On the basis of
these findings, we demonstrate the utility of cellular RNA and
protein levels as a biomarker of atherosclerosis in this experimen-
tal Apoe/ model. In addition, we show a similar expression pat-
tern in human circulating cells. Further investigations in humans
will have to be performed to determine a possible clinical utility of
our findings.
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Figure S1 Levels of CD36 mRNA in Circulating Leucocytes Associ-
ates with FABP4 mRNA and Extent of Atherosclerotic Lesion in
Aorta. (A) Correlation of mRNA levels of FABP4 and CD36 in cir-
culating leucocytes from Apoe/ (12, 20 and 32 weeks of age)
as measured by RT-PCR TaqMan, n = 22 (r = 0.594
**P < 0.001). (B) Correlation between lesion area and CD36
mRNA, n = 22 (r = 0.675, ***P < 0.0001).
Figure S2 Monocyte Subsets in Apoe/ and C57BL/6. Flow cytome-
try on circulating leucocytes from Apoe/ (A) and C57BL/6 (B)
(12, 20 and 32 weeks of age). Graphs showing the percentage of the
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inflammatory monocyte subtype Ly6CHigh versus Ly6Clow. The mono-
cytes were defined as CD3, B220, DX5 NK1.1 C11clow,
CD11b+ and Ly6G and further divided into Ly6CHigh or Ly6Clow.
(C) Representative flow cytometry plots showing CD11b+ Ly6CHigh and
CD11b+ Ly6Clow from Apoe/ 12 and 32 weeks of age (**P < 0.001, ns
indicates not significant).
Table S1: Differential Blood Count in Apoe/ and C57BL/6.
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